NEW YORK, Jan. 28 - Beckman Coulter on Monday reported that fourth-quarter earnings swelled more than 12 percent to $48.3 million, or 75 cents per share, nudged by robust sales growth of its robotic genetic analysis tools.
The company added that a greater than 16 percent rise in European sales helped increase total revenue by 10 percent to $578.3 million from $525.3 million in the year-ago period.
Sales in the quarter ended Dec. 31 were driven by a 13.2 percent increase in the company's immunodiagnostics products, which reached $107.2 million, and a 34.5 percent climb in robotic genetic analysis product sales, which generated $60 million.
Beckman Coulter predicts that 2002 will see sales rising 7 percent to 8 percent, and earnings growing 18 percent to 20 percent. So far this fiscal first quarter, the company estimates an earnings increase of roughly 20 percent, with sales up by approximately 7 percent.
The Fullerton, Calif.-based firm also said that it will report sales from three categories beginning in the first quarter. The categories will be clinical diagnostics, life-science research, and specialty testing.